3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
Clinical Update 5/15/2021 Misleading Kefir Claims Recent testing of several popular kefir beverages in the U.S
Purity and a certificate of analysis matter more here than the lowest price on the page, because a clean sample is the starting point for any meaningful result
- Annalise Slezak This liquid B12 has improved my energy levels without any side effects
If there are signs of NAD+ deficiency, such as in pellagra, which manifests as dermatitis, dementia, or diarrhea, supplemental IV NAD therapy may be warranted
We provide clear, upfront pricing during your consultation and work with you to design an affordable plan